enVVeno Medical Corp NVNO
Medical Corporation is a medical device company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve
the standard of care for the treatment of venous disease. Chronic Venous Disease ("CVD") is the world's most prevalent
chronic disease, impacting approximately 70% of the adult population of the U.S. Chronic Venous Insufficiency ("CVI"), is
a large subset of CVD, which most often occurs when valves inside of the veins of the leg become damaged, resulting in the backwards
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $31.2K | $186.6K | $422.1K | — |
| Cost of revenue | — | — | — | — | — | — | — | — | $419.7K | — |
| Gross profit | — | — | — | — | — | — | — | $186.6K | $2.5K | — |
| R&D | $10.0M | $12.2M | $13.6M | $9.9M | $5.7M | $4.3M | $2.2M | $1.2M | $649.7K | — |
| SG&A | $10.9M | $11.6M | $11.7M | $15.0M | $11.2M | $4.9M | $4.9M | $6.5M | $5.5M | — |
| Operating income | -$20.9M | -$23.8M | -$25.2M | -$24.9M | -$16.9M | -$9.1M | -$7.7M | -$7.9M | -$6.1M | — |
| Interest expense | — | — | — | $161.0K | $19.0K | $3.7K | $49.9K | $298.2K | — | — |
| Pre-tax income | -$19.5M | -$21.8M | — | — | — | — | — | — | — | — |
| Net income | -$19.5M | -$21.8M | -$23.5M | -$24.7M | -$16.5M | -$9.1M | -$7.6M | -$13.0M | -$7.8M | — |
| EPS, basic | -33.06 | -44.53 | -1.91 | -2.20 | -1.90 | — | — | — | — | — |
| EPS, diluted | -33.06 | -44.53 | -1.91 | -2.20 | -1.90 | -7.54 | -12.10 | -1.75 | -1.35 | — |
| Shares, diluted (wtd. avg.) | $589.0K | $490.0K | $12.3M | $11.2M | $8.7M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $3.1M | $1.8M | $3.6M | $4.6M | $54.7M | $9.3M | $1.3M | $2.7M | $77.7K | $56.5K |
| Short-term investments | $25.1M | $41.4M | $42.8M | $34.5M | — | — | — | — | — | — |
| Receivables | — | — | — | — | — | — | — | $32.0K | $35.2K | — |
| Total current assets | $28.8M | $43.7M | $46.9M | $39.4M | $55.0M | $9.6M | $1.4M | $2.8M | $170.4K | — |
| Property, plant and equipment | $51.0K | $182.0K | $334.0K | $521.0K | $618.0K | $399.0K | $344.0K | $26.2K | $23.8K | — |
| Other intangibles | — | — | — | — | — | — | — | $666.5K | $1.1M | — |
| Total assets | $29.6M | $45.0M | $48.6M | $41.7M | $57.7M | $10.5M | $3.4M | $3.6M | $2.2M | — |
| Accounts payable | $358.0K | $1.0M | $1.0M | $1.2M | $560.0K | $1.4M | $1.2M | $1.1M | $1.5M | — |
| Total current liabilities | $2.1M | $2.1M | $1.4M | $1.5M | $1.6M | $3.2M | $1.9M | $1.5M | — | — |
| Total liabilities | $2.4M | $2.8M | $2.4M | $2.9M | $3.3M | $3.4M | $2.4M | $1.5M | $8.2M | — |
| Retained earnings | -$171.3M | -$151.9M | -$130.0M | -$106.5M | -$81.9M | -$65.3M | -$56.2M | -$48.6M | -$35.5M | — |
| Total equity | $27.1M | $42.2M | $46.2M | $38.7M | $54.4M | $7.1M | $989.9K | $2.0M | -$11.1M | -$4.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.6M | -$16.8M | -$18.9M | -$15.6M | -$11.8M | -$7.7M | -$5.9M | -$6.4M | -$4.2M | — |
| Depreciation and amortisation | $100.0K | $200.0K | $200.0K | $200.0K | $100.0K | $100.0K | $46.0K | $10.1K | $15.9K | — |
| Stock-based compensation | $3.4M | $4.1M | $5.2M | $9.0M | $6.0M | $881.2K | $942.0K | $1.9M | $878.4K | — |
| Capital expenditure | $5.0K | $37.0K | $33.0K | $115.0K | $368.0K | $180.3K | $363.9K | $12.4K | $10.9K | — |
| Investing cash flow | $15.9M | $1.3M | -$7.9M | -$34.6M | -$368.0K | -$180.3K | -$363.9K | -$12.4K | $165.3K | — |
| Financing cash flow | $1.0M | $13.6M | $25.8M | — | $57.6M | $15.1M | $5.6M | $9.0M | $4.1M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-012928.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $116.27B | 36.1x | 11.2% |
| MMM | 3M CO | $86.93B | 28.1x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $69.27B | 24.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $50.32B | 31.7x | 8.2% |
| DXCM | DEXCOM INC | $33.17B | 42.1x | 15.6% |
| RMD | RESMED INC | $32.94B | 21.9x | 9.9% |
| MDLN | Medline Inc. | $31.35B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $23.93B | 50.1x | 6.3% |